glycemic

Trelagliptin succinate (SYR-472 succinate) is a long-acting inhibitor of dipeptidyl peptidase-4 (DPP-4), being developed for the treatment of type 2 diabetes (T2D).

Hypoglycemic agent 1 has an action for lowering blood sugar. It acts as a therapeutic and/or prophylactic agent for diabetes.

Compound H26, a derivative of corosolic acid, functions as Hypoglycemic agent 3. It exhibits lipid-lowering and significant blood glucose-reducing properties, making it a potential hypoglycemic drug. Hypoglycemic agent 3 targets MCCC1 to mitigate insulin resistance, and may be useful in researching type 2 diabetes.

Anti-hyperglycemic agent 1 is a potent inhibitor of alpha-glucosidase (IC50: 0.53 μM). anti-Hyperglycemic agent 1 can be used to study diabetes.

Rosiglitazone (BRL49653) is a PPARγ agonist, TRPC5 activator, and TRPM3 inhibitor with oral activity. Rosiglitazone is also a hypoglycemic agent and a thiazolidinedione insulin sensitizer.

Acarbose (BAY g 5421) is a hypoglycemic agent that is an inhibitor of orally active alpha-glucosidase (IC50=11 nM). Acarbose enhances the hypoglycemic effect of sulfonylureas or insulin.

Methyldopa (MK-351), an alpha-adrenergic agonist (selective for α2-adrenergic receptors) psychoactive medicine, is served as an antihypertensive or sympatholytic.

Vildagliptin (LAF237) is a cyanopyrrolidine-based, orally bioavailable inhibitor of dipeptidyl peptidase 4 (DPP-4), with hypoglycemic activity. Vildagliptin's cyano moiety undergoes hydrolysis and this inactive metabolite is excreted mainly via the urine.

Catalpol (Catalpinoside) is an iridoid glycoside with neuroprotective, anti-inflammatory, and anti-hepatitis virus effects.

1-Deoxynojirimycin (Moranoline) is a potent α-glucosidase inhibitor, suppressing postprandial blood glucose, thereby possibly preventing diabetes mellitus.

Methyldopa hydrate (MK-351 hydrate) is a DOPA decarboxylase inhibitor and indirect α2-adrenergic receptor agonist used to treat hypertension. It inhibits the sympathetic nervous system, decreases production of dopamine, norepinephrine, and epinephrine, and exhibits NO-dependent sedative activity.

Rosiglitazone hydrochloride (BRL-49653 HCl) is a blood glucose-lowering drugs, stimulating insulin secretion by binding to the PPAR receptors in fat cells.

Sari 59-801 is a novel, orally effective hypoglycemic compound.

1-Deoxynojirimycin hydrochloride (Moranoline) is a potent and selective inhibitor of alpha-glucosidase, most commonly found in mulberry leaves. Duvoglustat is used to suppress the elevation of postprandial hyperglycemia.

AZD-1656 is a glucokinase activator (GKA) that can cause dose-limiting hypoglycemia in normal animals used in embryofetal development studies and type 2 diabetes.

Nomilin is naturally occurring triterpenoids, have immunomodulatory activity.

Rhapontigenin (Protigenin) is a mechanism-based, selective inactivator of cytochrome P450 1A1 (IC50: 400 nM), an aryl hydrocarbon hydroxylase which activates polycyclic aromatic hydrocarbons that act as procarcinogens. Rhapontigenin is a natural analog of resveratrol with antioxidant and anti-cancer activity. At higher concentrations, rhapontigenin inhibits the proliferation of HL-60R and HepG2 cancer cell lines (IC50: 48 μM).

Glucagon significantly impacts protein and amino acid metabolism. It hinders the integration of amino acids into the proteins of the liver, muscle, and pancreas, augmenting nitrogen excretion and stimulating hepatic urea synthesis. Additionally, it elevates hepatic transaminase and urea cycle enzyme levels. Glucagon also enhances hepatic amino acid uptake, facilitating their conversion into liver glycogen, and reduces blood amino acid concentrations [1].

Butyl isobutyl phthalate (ButylIsobutylPhthalate) is a non-competitive α-glucosidase inhibitor(IC50 :38 μM),it shows a hypoglycemic effect

Carbutamide is a sulfonylurea antidiabetic agent with hypoglycemic activity.

Metformin hydrochloride (1,1-Dimethylbiguanide hydrochloride), a widely used anti-diabetic drug, exhibits potential anti-Y properties by inhibiting the proliferation of various Y cells, including colon and prostate.

Metformin (1,1-Dimethylbiguanide) is an AMPK activator with blood-brain barrier permeability. Metformin may improve glycemic control by increasing insulin sensitivity and decreasing intestinal glucose uptake, and is commonly used in type 2 diabetes research.

2,2'-Bipyridine is a unique bioactive natural product molecular scaffold commonly used in the core structure of many chelating ligands. 2,2'-Bipyridine acts as a bridge in the arrangement of the catalytic center. 2,2'-Bipyridine has good redox stability and glycemic activity.

Epalrestat (ONO2235), an aldose reductase inhibitor, is well tolerated in Long-term therapy. It can effectually ameliorate the associated symptoms of diabetic neuropathy and delay the progression of the disease, particularly in patients with limited microangiopathy and good glycemic control.